Profile data is unavailable for this security.
About the company
Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2 vaccines; and colorectal cancer, offering CV-301 colon. The Infectious Disease pipeline produces vaccines for a range of illnesses, such as smallpox, anthrax, filoviruses, foot-and-mouth diseases and respiratory syncytial virus. The Company is a parent of Bavarian Nordic GmbH, BN Infectious Diseases A/S, and Bavarian Nordic Inc, among others.
- Revenue in DKK (TTM)7.06bn
- Net income in DKK1.48bn
- Incorporated1992
- Employees1.38k
- LocationBavarian Nordic A/SPhilip Heymans Alle 3HELLERUP 2900DenmarkDNK
- Websitehttps://www.bavarian-nordic.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nykode Therapeutics ASA | 90.15m | -245.64m | 2.67bn | 168.00 | -- | 2.23 | -- | 29.56 | -1.39 | -1.39 | 0.5151 | 5.76 | 0.0601 | -- | 10.14 | -- | -16.36 | 5.65 | -19.00 | 6.38 | -- | -- | -272.47 | 18.13 | -- | -- | 0.0324 | -- | 79.99 | 282.17 | 17.75 | -- | 187.37 | -- |
| Calliditas Therapeutics AB | 771.26m | -297.92m | 3.84bn | 181.00 | -- | 16.18 | -- | 4.98 | -8.69 | -8.69 | 22.49 | 6.24 | 0.6332 | 5.02 | 8.77 | 6,667,895.00 | -24.46 | -26.46 | -30.27 | -30.27 | 94.99 | -- | -38.63 | -76.59 | 3.08 | -4.44 | 0.7427 | -- | 50.32 | -- | -13.08 | -- | -- | -- |
| Surgical Science Sweden AB | 564.19m | 149.52m | 4.80bn | 260.00 | 32.10 | 1.73 | 25.95 | 8.51 | 4.59 | 4.59 | 17.32 | 85.16 | 0.1888 | 1.87 | 6.15 | 3,395,589.00 | 5.00 | 4.49 | 5.31 | 4.78 | 69.42 | 70.06 | 26.50 | 23.75 | 3.56 | -- | -- | 0.00 | 10.01 | 68.14 | 24.47 | -- | 38.57 | -- |
| Gubra A/S | 205.01m | -44.52m | 4.97bn | 219.00 | -- | 10.32 | -- | 24.24 | -2.91 | -2.91 | 13.51 | 29.44 | -- | -- | -- | 936,095.90 | -- | -- | -- | -- | 56.06 | -- | -21.72 | -- | -- | -- | 0.1296 | -- | 2.82 | -- | -1,133.04 | -- | -- | -- |
| Swedencare AB (publ) | 1.49bn | 37.45m | 6.09bn | 486.00 | 162.52 | 1.32 | 25.85 | 4.07 | 0.3692 | 0.3692 | 14.73 | 45.40 | 0.2395 | 2.50 | 10.23 | 4,811,523.00 | 0.6002 | 1.38 | 0.6195 | 1.43 | 55.20 | 55.34 | 2.51 | 5.10 | 1.99 | 1.96 | 0.1871 | 45.33 | 27.48 | 88.16 | -37.96 | 20.24 | 30.90 | -- |
| AddLife AB | 6.19bn | 122.06m | 7.37bn | 2.30k | 62.46 | 2.41 | 10.29 | 1.19 | 1.57 | 1.57 | 79.48 | 40.69 | 0.7507 | 3.69 | 6.94 | 4,209,040.00 | 1.49 | 5.31 | 2.25 | 8.83 | 37.16 | 36.88 | 1.98 | 5.79 | 0.4541 | 1.66 | 0.5085 | 31.73 | 6.62 | 31.30 | -60.42 | 8.00 | 44.43 | -1.89 |
| BioGaia AB | 828.53m | 233.48m | 7.46bn | 210.00 | 33.17 | 5.97 | 29.88 | 9.00 | 3.62 | 3.62 | 12.84 | 20.11 | 0.5703 | 2.14 | 10.96 | 6,173,838.00 | 16.07 | 15.47 | 17.45 | 16.93 | 73.29 | 73.30 | 28.18 | 27.70 | 8.65 | -- | 0.0043 | 104.42 | 17.44 | 11.81 | -2.25 | 11.20 | 29.27 | 28.10 |
| BioArctic AB | 393.65m | 146.50m | 9.27bn | 83.00 | 76.42 | 16.62 | 58.59 | 23.56 | 2.58 | 2.58 | 6.97 | 11.85 | 0.6026 | -- | -- | -- | 22.43 | 2.24 | 24.80 | 2.56 | 91.73 | 86.52 | 37.22 | 9.76 | -- | -- | 0.0047 | 0.00 | 169.83 | -2.91 | 2,150.71 | -9.69 | -- | -- |
| Bonesupport Holding AB | 377.73m | 156.58m | 10.00bn | 110.00 | 64.01 | 28.92 | 62.01 | 26.49 | 3.72 | 3.72 | 9.04 | 8.24 | 1.11 | 0.7186 | 6.60 | 5,373,428.00 | 46.20 | -9.08 | 58.31 | -11.28 | 91.51 | 90.25 | 41.45 | -11.65 | 2.46 | -- | 0.0311 | -- | 79.76 | 43.65 | 459.44 | -- | 18.39 | -- |
| Bavarian Nordic A/S | 7.06bn | 1.48bn | 11.64bn | 1.38k | 7.66 | 1.12 | 5.74 | 1.65 | 19.46 | 19.46 | 92.83 | 132.47 | 0.5281 | 1.92 | 6.10 | 5,121,349.00 | 11.03 | 1.21 | 13.62 | 1.48 | 65.18 | 53.72 | 20.89 | 4.06 | 1.35 | -- | 0.0139 | 0.00 | 124.14 | 69.78 | 524.66 | -- | 35.76 | -- |
| Vitrolife AB | 2.24bn | -2.46bn | 15.78bn | 1.08k | -- | 1.94 | -- | 7.03 | -28.44 | -28.44 | 25.94 | 93.96 | 0.1905 | 3.75 | 7.34 | 3,254,866.00 | -20.88 | -4.57 | -21.58 | -4.78 | 56.32 | 58.38 | -109.65 | -21.89 | 2.69 | -28.98 | 0.141 | -- | 8.60 | 24.99 | -1,077.41 | -- | -7.95 | 3.30 |
| Camurus AB | 1.10bn | 275.71m | 18.33bn | 213.00 | 66.42 | 18.55 | 64.40 | 16.71 | 7.49 | 7.49 | 30.11 | 26.84 | 1.07 | 1.17 | 7.29 | 8,060,329.00 | 26.85 | -1.13 | 33.67 | -1.41 | 92.87 | 90.05 | 25.13 | -1.63 | 4.13 | -- | 0.0162 | -- | 79.52 | 103.39 | 676.63 | -- | 16.29 | -- |
| ALK-Abello A/S | 4.82bn | 486.00m | 25.56bn | 2.82k | 60.32 | 6.28 | 32.90 | 5.30 | 2.09 | 2.09 | 20.90 | 20.10 | 0.7402 | 1.32 | 6.11 | 1,708,215.00 | 7.46 | 3.50 | 9.42 | 4.37 | 62.91 | 60.66 | 10.07 | 5.07 | 1.18 | 35.05 | 0.1468 | 0.00 | 6.94 | 10.60 | 45.07 | -- | 16.32 | -- |
Data as of Apr 18 2024. Currency figures normalised to Bavarian Nordic A/S's reporting currency: Danish Krone DKK
20.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ATP Arbejdsmarkedets Till�gspensionas of 31 Dec 2022 | 7.16m | 9.17% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 2.30m | 2.95% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 1.64m | 2.10% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 1.22m | 1.56% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 1.07m | 1.37% |
| Nykredit Bank A/S (Investment Management)as of 31 Mar 2024 | 929.30k | 1.19% |
| Victory Capital Management, Inc. (Investment Management)as of 31 Jan 2024 | 609.35k | 0.78% |
| Handelsbanken Fonder ABas of 31 Mar 2024 | 566.80k | 0.73% |
| Oddo BHF Asset Management SASas of 29 Feb 2024 | 444.00k | 0.57% |
| AllianceBernstein Ltd.as of 29 Feb 2024 | 346.58k | 0.44% |
More ▼
Data from 31 Dec 2023 - 09 Apr 2024Source: FactSet Research Systems Inc.
